Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($1.51), $1.37 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $11 million versus the consensus estimate of $6.35 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.